Close Menu

NEW YORK (GenomeWeb) – Researchers have uncovered a common genetic variant that is associated with liver injury in multiple sclerosis patients who have been treated with interferon-β, suggesting a new way to pick out patients at risk of the adverse reaction.

IFN-βs are the most commonly used treatments for multiple sclerosis, but up to 60 percent of patients given the drug develop abnormal biochemical liver test results and 2 percent experience drug-induced liver injury.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.